Ex­clu­sive: No­cion rais­es $62M for dif­fer­ent ap­proach to chron­ic cough than Mer­ck, GSK

In the mid­dle of 2023, Richard Baty­cky told a cou­ple of his fel­low ex­ec­u­tives at No­cion Ther­a­peu­tics to con­sid­er look­ing for roles else­where. He wasn’t sure the biotech would weath­er a dif­fi­cult fund­ing land­scape.

Then, as the CEO was prepar­ing for a va­ca­tion, a term sheet from an in­vestor came through. Signs of a brighter day were ahead and Baty­cky would spend the next sev­er­al months pulling to­geth­er a $62 mil­lion Se­ries B to fund No­cion’s in­haled chron­ic cough can­di­date NTX-1175, which will now be known un­der the name ta­plu­ca­ni­um, he told End­points News in an ex­clu­sive in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER